Invention Application
- Patent Title: CYP11A1 INHIBITORS
-
Application No.: US18708157Application Date: 2022-11-09
-
Publication No.: US20250011285A1Publication Date: 2025-01-09
- Inventor: David DIN BELLE , Pekka PIETIKÄINEN , Petteri RUMMAKKO , Gerd WOHLFAHRT
- Applicant: ORION CORPORATION
- Applicant Address: FI Espoo
- Assignee: ORION CORPORATION
- Current Assignee: ORION CORPORATION
- Current Assignee Address: FI Espoo
- Priority: FI20217169 20211110
- International Application: PCT/FI2022/050741 WO 20221109
- Main IPC: C07D209/44
- IPC: C07D209/44 ; A61K31/4035 ; A61K31/423 ; A61K31/454 ; A61K31/4709 ; A61K45/06 ; C07D209/46 ; C07D401/06 ; C07D401/12 ; C07D401/14 ; C07D413/06 ; C07D413/14

Abstract:
The present invention relates to a compound of formula (I) wherein A, B, R1, R2, R3, R4 and R5 are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, for example androgen receptor or estrogen receptor, dependent diseases and conditions, such as cancer including prostate cancer and breast cancer.
Information query